Hong Kong Prohibits CBD Products: 7-Year Imprisonment and Heavy Fines

Jan.12.2023
Hong Kong Prohibits CBD Products: 7-Year Imprisonment and Heavy Fines
Hong Kong bans all CBD products, adding them to its Dangerous Drugs Ordinance, with the possibility of severe punishments.

Hong Kong, China recently announced that all products containing cannabidiol (CBD) will be banned starting February 1st. CBD will be added to the Dangerous Drugs Ordinance (DDO), which already includes over 200 substances such as fentanyl, ketamine, heroin, and various psychoactive compounds like MDMA.


CBD will now be included in the existing list of "cannabinol and its tetrahydro derivative (THC); as well as 3-alkyl homologues." As a result of this change, anyone who possesses or consumes CBD will face a maximum of seven years in prison and a fine of up to HKD 1 million (approximately RMB 870,000).


According to Lexology, manufacturers of CBD may also face life imprisonment.


Although many users around the world have been touting the anti-anxiety and pain-relieving properties of CBD, the Hong Kong Security Bureau believes that these claims "lack authoritative scientific evidence." This directive appears to be consistent with China's ban on the use of CBD in cosmetics implemented last year.


Currently, it is unclear whether other cannabinoids such as CBG, CBDV, CBC, etc. will be included in the ban. However, based on a memorandum from the Narcotics Division in November 2022, the Hong Kong government appears to be primarily concerned about the possibility of CBD products containing trace amounts of THC, either through breakdown or conversion, and the lack of international regulations specifically for these products.


Article Related Reading: Hong Kong plans to completely ban the sale of CBD products by the end of 2022.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
India has reaffirmed its 2019 ban on e-cigarettes and heated tobacco devices, effectively blocking Philip Morris International (PMI) from launching IQOS in the country despite years of lobbying. Together with Taiwan, China’s conditional opening of heated tobacco products, and Japan’s planned 2026 excise tax hikes, these moves highlight increasingly divergent national regulatory pathways—an external uncertainty shaping PMI’s smoke-free growth trajectory.
Feb.12
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Nilüfer Municipality in Bursa held a scientific talk titled “Does Addiction Change Form? Cigarettes, E-Cigarettes and Lung Health” as part of February 9 Quit Smoking Day, aiming to raise awareness of the social impact of tobacco addiction. Experts discussed cigarette and e-cigarette addiction, risks for young people, harms of secondhand smoke for children, and health outcomes linked to tobacco use.
Feb.10 by 2FIRSTS.ai
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar’s Ministry of Health said it has received cabinet authorization to enforce an e-cigarette ban under the Essential Supplies and Services Law, listing prohibited acts including the import, export, sale, possession, storage, carrying, distribution and use of vaping products.
Feb.26 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Product | Lost Vape launches “4D portable shisha” device with 3,800mAh battery and up to 80W output
Product | Lost Vape launches “4D portable shisha” device with 3,800mAh battery and up to 80W output
E-cigarette brand Lost Vape has recently listed its open-system DTL device, the ASTARA, on its official website. The company markets the product as “The First 4D Portable Shisha Experience,” highlighting a 360-degree display and audio features. The ASTARA has also appeared on some online sales channels in markets including the UK and Germany.
Feb.03 by 2FIRSTS.ai